Trypsin treatment unlocks barrier for zoonotic coronaviruses infection
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
Isolation and Characterization of 2019-nCoV-like Coronavirus from Malayan Pangolins
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor
SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
Potential T-cell and B-cell Epitopes of 2019-nCoV
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Functional pangenome analysis provides insights into the origin, function and pathways to therapy of SARS-CoV-2 coronavirus
Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2
Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2
A human monoclonal 1 antibody blocking SARS-CoV-2 infection
Differential Antibody Recognition by Novel SARS-CoV-2 and SARS-CoV Spike Protein Receptor Binding Domains: Mechanistic Insights
A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV
SARS-CoV-2 invades host cells via a novel route: CD147-spike protein
A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections
Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies
SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution
Fully human single-domain antibodies against SARS-CoV-2
Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein
SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro
3D Models of glycosylated SARS-CoV-2 spike protein suggest challenges and opportunities for vaccine development
Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells
Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing
On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2
De novo design of high-affinity antibody variable regions (scFv) against the SARS-CoV-2 spike protein
Structural interactions between pandemic SARS-CoV-2 spike glycoprotein and human Furin protease
The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement
Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine
Genome based Evolutionary study of SARS-CoV-2 towards the Prediction of Epitope Based Chimeric Vaccine
Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain
Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy
Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals
Elucidating the differences in the molecular mechanism of receptor binding between 2019-nCoV and the SARS-CoV viruses using computational tools
Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19
ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19
Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy
Structural and Functional Implications of Non-synonymous Mutations in the Spike protein of 2,954 SARS-CoV-2 Genomes
Isolating multiple formats of human monoclonal neutralizing antibodies against SARS-CoV-2 by in vitro site-directed antibody screening
Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool
Neutralization of SARS-CoV-2 by destruction of the prefusion Spike
Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles
A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability
Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients
Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Antibody repertoire induced by SARS-CoV-2 spike protein immunogens
CoV3D: A database of high resolution coronavirus protein structures
A rapid, point of care red blood cell agglutination assay for detecting antibodies against SARS-CoV-2
Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody
Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals
IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity
CoV-AbDab: the Coronavirus Antibody Database
Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities
Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement
Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T cell memory formation after mild COVID-19 infection
Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19
Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
Isolation of and Characterization of Neutralizing Antibodies to Covid-19 from a Large Human NaiÌˆve scFv Phage Display Library
High Throughput Designing and Mutational Mapping of RBD-ACE2 Interface Guide Non-Conventional Therapeutic Strategies for COVID-19
Human IgG cell neutralizing monoclonal antibodies block SARS-CoV-2 infection
Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In Covid-19 Patients Semiquantitatively.
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals
Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2
SARS-CoV-2 genomics beyond the consensus sequence: evidence for circulating mixed viral populations
Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
"Monoclonal-type" plastic antibodies for SARS-CoV-2 based on Molecularly Imprinted Polymers
Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
Optimized pseudotyping conditions for the SARS-COV2 Spike glycoprotein
Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients
Neuropilin-1 is a host factor for SARS-CoV-2 infection
A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells
Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients.
Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike
Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Structural basis of a public antibody response to SARS-CoV-2
Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins
Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection
Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization
The Distal Polybasic Cleavage Sites of SARS-CoV-2 Spike Protein Enhance Spike Protein-ACE2 Binding
Shielding and Beyond: The Roles of Glycans in SARS-CoV-2 Spike Protein
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients
Validation and performance of a quantitative IgG assay for the screening of SARS-CoV-2 antibodies
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease
A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
Interfacial Water Molecules Make RBD of SPIKE Protein and Human ACE2 to Stick Together
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform
Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike
Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs
A single dose of recombinant VSV-{triangleup}G-spike vaccine provides protection against SARS-CoV-2 challenge
Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2 Infected Syrian Hamsters
Private Antibody Repertoires Are Public
SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients
Endemic human coronaviruses induce distinct antibody repertoires in adults and children
Companion vaccine Bioinformatic design tool reveals limited functional genomic variability of SARS-Cov-2 Spike Receptor Binding Domain
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Green tea and Spirulina extracts inhibit SARS, MERS, and SARS-2 spike pseudotyped virus entry in vitro
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor
Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response
Critical Sequence Hot-spots for Binding of nCOV-2019 to ACE2 as Evaluated by Molecular Simulations
Stereotypic Neutralizing VH Clonotypes Against SARS-CoV-2 RBD in COVID-19 Patients and the Healthy Population
A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection
A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies
Using iCn3D and the World Wide Web for structure-based collaborative research: Analyzing molecular interactions at the root of COVID-19
Association between neutralizing antibodies to SARS-CoV-2 and commercial serological assays
Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine
Map of SARS-CoV-2 spike epitopes not shielded by glycans.
A pH-dependent switch mediates conformational masking of SARS-CoV-2 spike
SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain
A rapidly adaptable biomaterial vaccine for SARS-CoV-2
Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike
Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis
Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency
Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2
Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals
A simple protein-based SARS-CoV-2 surrogate neutralization assay
A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine
The antibody response to the glycan Î±-Gal correlates with COVID-19 disease symptoms
Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization
Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors
De novo design of modular and tunable allosteric biosensors
S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit
Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2.
Intranasal Immunization with a Lentiviral Vector Coding for SARS-CoV-2 Spike Protein Confers Vigorous Protection in Pre-Clinical Animal Models
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Virus-free and live-cell visualizing SARS-CoV-2 cell entry for studies of neutralizing antibodies and compound inhibitors
SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
The answer lies in the energy: how simple atomistic molecular dynamics simulations may hold the key to epitope prediction on the fully glycosylated SARS-CoV-2 spike protein
High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2
CoVaccine HTâ„¢ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation
The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV
An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries
Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
Study on Î²-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2
SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay
REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Binding Ligands that Straddle an Important Contact Site on the RBD of the Covid-19 Spike Protein
A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-CoV-2 infection
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Peptide Antidotes to SARS-CoV-2 (COVID-19)
Ig-VAE: Generative Modeling of Immunoglobulin Proteins by Direct 3D Coordinate Generation
A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples
An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
A 3.4-A cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles
Rapid endothelialitis and vascular inflammation characterise SARS-CoV-2 infection in a human lung-on-chip model
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells
Attenuated influenza virions expressing the SARS- CoV-2 receptor-binding domain induce neutralizing antibodies in mice
The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer
SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry
Designed Variants of Recombinant ACE2-Fc that Decouple Anti-SARS-CoV-2 Activities from Unwanted Cardiovascular Effects
Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine
Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model
High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.
Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapy
A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
IFITM proteins promote SARS-CoV-2 infection in human lung cells
Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid
A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD
Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay
COVID-19 and Cholinergic Anti-inflammatory Pathway: In silico Identification of an Interaction between alpha7 Nicotinic Acetylcholine Receptor and the Cryptic Epitopes of SARS-CoV and SARS-CoV-2 Spike Glycoproteins
Limited window for donation of convalescent plasma with high live-virus neutralizing antibodies for COVID-19 immunotherapy
Recombinant SARS-CoV-2 RBD molecule with a T helper epitope as a built in adjuvant induces strong neutralization antibody response
The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera.
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein
Pathogenicity, immunogenicity, and protective ability of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein
Versatile, Multivalent Nanobody Cocktails for Highly Efficient SARS-CoV-2 Neutralization
The influence of major S protein mutations of SARS-CoV-2 on the potential B cell epitopes
Multi-species ELISA for the detection of antibodies against SARS-CoV-2 in animals
Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis
The immunodominant and neutralization linear epitopes for SARS-CoV-2
Immune response to vaccine candidates based on different types of nanoscaffolded RBD domain of the SARS-CoV-2 spike protein
A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans
Establishment of murine hybridoma cells producing antibodies against spike protein of SARS-CoV-2
Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
Prime-boost protein subunit vaccines against SARS-CoV-2 are highly immunogenic in mice and macaques
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies
Boosting the analysis of protein interfaces with Multiple Interface String Alignment: illustration on the spikes of coronaviruses
Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.
Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles
A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD
A COVID-19 antibody curbs SARS-CoV-2 nucleocapsid protein-induced complement hyper-activation
Single-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammation
SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike
Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines
High affinity modified ACE2 receptors prevent SARS-CoV-2 infection
The flexibility of ACE2 in the context of SARS-CoV-2 infection
Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing
Efficient production of Moloney murine leukemia virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein
Distinct SARS-CoV-2 Antibody Reactivity Patterns in Coronavirus Convalescent Plasma Revealed by a Coronavirus Antigen Microarray
A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture
Structural and Functional Comparison of SARS-CoV-2-Spike Receptor Binding Domain Produced in Pichia pastoris and Mammalian Cells
Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model
An immunodominance hierarchy exists in CD8+ T cell responses to HLA-A*02:01-restricted epitopes identified from the non-structural polyprotein 1a of SARS-CoV-2.
Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor
A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
AI-guided discovery of the invariant host response to viral pandemics
NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2
A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters
A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force
Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2
Prime-boost vaccination of mice and Rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates
SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ex vivo and Earlier Transmission in vivo
Design, expression, purification and characterization of a YFP-tagged 2019-nCoV spike receptor-binding domain construct
A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core
BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19
Autoproteolytic Products of the SARS-CoV-2 Nucleocapsid Protein are Primed for Antibody Evasion and Virus Proliferation
Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors
Extremely potent human monoclonal antibodies from convalescent Covid-19 patients
Production of ORF8 protein from SARS-CoV-2 using an inducible virus-mediated expression-system in suspension-cultured tobacco BY-2 cells
CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entireSARS-CoV-2 proteome and show kinetics of early differentiation
SARS-CoV-2 Elicits Robust Adaptive Immune Responses Regardless of Disease Severity
Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice
The landscape of antibody binding to SARS-CoV-2
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities
Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal Antibodies
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
Evidence of antigenic imprinting in sequential Sarbecovirus immunization
Quantitative Assays Reveal Cell Fusion at Minimal Levels of SARS-CoV-2 Spike Protein and Fusion-from-Without
Design of SARS-CoV-2 RBD mRNA Vaccine Using Novel Ionizable Lipids
Ongoing Adaptive Evolution and Globalization of Sars-Cov-2
Peptide vaccine candidate mimics the heterogeneity of natural SARS-CoV-2 immunity in convalescent humans and induces broad T cell responses in mice models
Antibody Response to a Nucleocapsid Epitope as a Marker for COVID-19 Disease Severity
Structure, Dynamics, Receptor Binding, and Antibody Binding of Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane
Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein
High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples
Preclinical study of DNA vaccines targeting SARS-CoV-2
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine
Transferrin receptor is another receptor for SARS-CoV-2 entry
The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
Induced pulmonary comorbidities render CD-1 mice sensitive to SARS-CoV-2
Protective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model
Epitope profiling reveals binding signatures of SARS-CoV-2 immune response and cross-reactivity with endemic HCoVs
A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies
PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate
The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition
Early immune response in mice immunized with a semi-split inactivated vaccine against SARS-CoV-2 containing S protein-free particles and subunit S protein
Evolution of Antibody Immunity to SARS-CoV-2
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice
The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN
Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Protective efficacy of a SARS-CoV-2 DNA Vaccine in wild-type and immunosuppressed Syrian hamsters
Highly potent bispecific sybodies neutralize SARS-CoV-2
Rapid generation of potent antibodies by autonomous hypermutation in yeast
ACE2-Targeting Monoclonal Antibody As A "Pan" Coronavirus Blocker In Vitro and In A Mouse Model
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2
A Whole Virion Vaccine for COVID-19 Produced Via a Novel Inactivation Method:  Results from Animal Challenge Model Studies
High resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies
Trimeric SARS-CoV-2 Spike proteins produced from CHO-cells in bioreactors are high-quality antigens
Intranasal Administration of ACIS KEPTIDEâ„¢ Prevents SARS-CoV2-Induced Acute Toxicity in K18-hACE2 Humanized Mouse Model of COVID-19: A Mechanistic Insight for the Prophylactic Role of KEPTIDEâ„¢ in COVID-19
Mosaic RBD nanoparticles elicit neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2
Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes
Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Transmission and protection against re-infection in the ferret model with the SARS-CoV-2 USA-WA1/2020 reference isolate
N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2
Effect of RBD mutation (Y453F) in spike glycoprotein of SARS-CoV-2 on neutralizing antibody affinity
Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in non-human primate and mice
A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an Adeno Associated Virus Human Angiotensin-Converting Enzyme 2 (AAV hACE2) Mouse Model
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Designed proteins assemble antibodies into modular nanocages
Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues
MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection in vitro and in a hamster model of COVID-19
A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations
Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Virus Infection as an Innate Antiviral Mechanism
Comparative analysis of antigen-specific anti-SARS-CoV-2 antibody isotypes in COVID-19 patients
Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection
Distant Residues Modulate the Conformational Opening in SARS-CoV-2 Spike Protein
Engineered receptor binding domain immunogens elicit pan-coronavirus neutralizing antibodies
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases
Conformational diversity of CDR region during affinity maturation determines the affinity and stability of Sars-Cov-1 VHH-72 nanobody
Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4+ T cells and strong CD8+ T cell responses in mice
Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2
The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced Immunity
Identification of four linear B-cell epitopes on the SARS-CoV-2 spike protein able to elicit neutralizing antibodies
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
Molecular diversity analysis of the spike glycoprotein (S) gene from Hong Kong - China
A human coronavirus evolves antigenically to escape antibody immunity
An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine
Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions
A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.
Fatty Acid Synthase inhibition prevents palmitoylation of SARS-CoV2 SpikeProtein and improves survival of mice infected with murine hepatitis virus.
In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma
Binding strength and hydrogen bond numbers between Covid-19 RBD and HVR of antibody
Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, antiviral drugs, and viral mutations
The SARS-CoV-2 S1 spike protein mutation N501Y alters the protein interactions with both hACE2 and human derived antibody: A Free energy of perturbation study
Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by in silico affinity maturation and SPR assay
Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2
SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans
Structural basis for broad coronavirus neutralization
Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients
Lentiviral vector-based SARS-CoV-2 pseudovirus enables analysis of neutralizing activity in COVID-19 convalescent plasma
An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro
Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro
Engineering, production and characterization of Spike and Nucleocapsid structural proteins of SARS-CoV-2 in Nicotiana benthamiana as vaccine candidates against COVID-19
Process Development and Scale-up Optimization of the SARS-CoV-2 Receptor Binding Domain-Based Vaccine Candidate, RBD219-N1C1
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates
Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor
Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro
SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor
Self-organized stem cell-derived human lung buds with proximo-distal patterning and novel targets of SARS-CoV-2
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters
Neuropilin-1 Assists SARS-CoV-2 Infection by Stimulating the Separation of Spike Protein Domains S1 and S2
Vimentin binds to SARS-CoV-2 spike protein and antibodies targeting extracellular vimentin block in vitro uptake of SARS-CoV-2 virus-like particles
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naiÌˆve human antibody library
Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody
Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein
Targeting conserved viral virulence determinants by single domain antibodies to block SARS-CoV2 infectivity
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
A highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative elicits high titers of neutralizing antibodies
Anti-CoVid19 plasmid DNA vaccine induces a potent immune response in rodents by Pyro-drive Jet Injector intradermal inoculation
SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses
CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
Coevolutionary Analysis and Perturbation-Based Network Modeling of the SARS-CoV-2 Spike Protein Complexes with Antibodies: Binding-Induced Control of Dynamics, Allosteric Interactions and Signaling
Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein
GRP78 binds SARS-CoV-2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro
Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection.
Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
SARS-CoV-2 receptor binding mutations and antibody mediated immunity.
Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain
E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil
Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein
Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2
Coronavirus associated molecular mimicry common to SARS-CoV-2 peptide
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets
Characterization of Critical Determinants of ACE2-RBD Interaction
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii
Identification of a conserved neutralizing epitope present on spike proteins from highly pathogenic coronaviruses
Nanotraps for the containment and clearance of SARS-CoV-2
Enhanced immunogenicity of a synthetic DNA vaccine expressing consensus SARS-CoV-2 Spike protein using needle-free immunization
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
The basis of a more contagious 501Y.V1 variant of SARS-COV-2
Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain
Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
Potential global impact of the N501Y mutation on MHC-II presentation and immune escape
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
Multi-specific DARPin(R) therapeutics demonstrate very high potency against mutated SARS-CoV-2 variants in vitro
Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates
Serological Profile Of Specific Antibodies Against Dominant Antigens Of SARS-CoV-2 In Chilean COVID-19 Patients.
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques
Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants.
Insights on SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival
Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat RBD of SARS-CoV-2 spike protein protects mice against COVID-19
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies
A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding
Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2
A chicken IgY can efficiently inhibit the entry and replication of SARS-CoV-2 by targeting the ACE2 binding domain in vitro
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Live attenuated SARS-CoV-2 vaccine candidate: Protective immunity without serious lung lesions in Syrian hamsters
Single-Domain SARS-CoV-2 S1 and RBD Antibodies Isolated from Immunized Llama Effectively Bind Targets of the Wuhan, UK, and South African Strains in vitro
E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Potent neutralization antibodies induced by a recombinant trimeric Spike protein vaccine candidate containing PIKA adjuvant for COVID-19
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine
Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2
Rotavirus as an Expression Platform of the SARS-CoV-2 Spike Protein
ESC - a comprehensive resource for SARS-CoV-2 immune escape variants
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies
Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies : Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19
Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants
Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells
A missense variant effect prediction and annotation resource for SARS-CoV-2
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants
Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2
Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
Fragment-based computational design of antibodies targeting structured epitopes
Altered Sub-Genomic RNA Expression in SARS-CoV-2 B.1.1.7 Infections
Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice
Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell epitope mapping
Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility
Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants
Neutralization heterogeneity of United Kingdom and South-African SARS CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
Drug development of an affinity enhanced, broadly neutralizing heavy chain only antibody that restricts SARS-CoV-2 in hamsters
Structural Analysis of Spike Protein Mutations in an Emergent SARS-CoV-2 Variant from the Philippines
Spike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization
A recombinant ACE2 Triple Decoy that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variants
Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes
Development of Equine Immunoglobulin Fragment F(ab')2 with High Neutralizing Capability against SARS-CoV-2
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
A tandem-repeat dimeric RBD protein-based COVID-19 vaccine ZF2001 protects mice and nonhuman primates
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity
Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice
An Innovative antibody-based Plug-and-Play strategy for SARS-CoV-2
New SARS-CoV-2 lineages could evade CD8+ T-cells response
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant viruses is up to 10-fold reduced
Effects of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike on its Binding Affinity to ACE2 and Neutralizing Antibodies Revealed by Computational Analysis
Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif
SARS-CoV-2 Spike receptor-binding domain with a G485R mutation in complex with human ACE2
Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection
Epigallocatechin Gallate from Green Tea Effectively Blocks Infection of SARS-CoV-2 and New Variants by Inhibiting Spike Binding to ACE2 Receptor
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies
Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19
A bispecific monomeric nanobody induces SARS-COV-2 spike trimer dimers
Structural and energetic profiling of SARS-CoV-2 antibody recognition and the impact of circulating variants
CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
Structural modeling of the SARS-CoV-2 Spike/human ACE2 complex interface can identify high-affinity variants associated with increased transmissibility
Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains
Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers
Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2
B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets
Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
A lipid nanoparticle RBD-hFc mRNA vaccine protects hACE2 transgenic mice against lethal SARS-CoV-2 infection
A recombinant receptor-binding domain in trimeric form generates completely protective immunity against SARS-CoV-2 infection in nonhuman primates
Rapid characterization of spike variants via mammalian cell surface display
A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants
Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein
One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization
Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies
Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model
Bioinformatics analysis of SARS-CoV-2 RBD mutant variants and insights into antibody and ACE2 receptor binding
COVID-19 mRNA vaccines drive differential Fc-functional profiles in pregnant, lactating, and non-pregnant women
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boost
XAV-19, a novel swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike, efficiently neutralizes B.1.1.7 British and B.1.351 South-African variants.
The Up state of the SARS-COV-2 Spike homotrimer favors an increased virulence for new variants
Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape
Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity
Nasal delivery of single-domain antibodies improve symptoms of SARS-CoV-2 infection in an animal model
Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
Theoretical causes of the Brazilian P.1 and P.2 lineages of the SARS-CoV-2 virus through molecular dynamics
Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
Atypical N-glycosylation of SARS-CoV-2 impairs the efficient binding of Spike-RBM to the human-host receptor hACE2
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
Quantatitive Analysis of Conserved Sites on the SARS-CoV-2 Receptor-Binding Domain to Promote Development of Universal SARS-Like Coronavirus Vaccines
Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies
Prediction and evolution of the molecular fitness of SARS-CoV-2 variants: Introducing SpikePro
Epitope profiling of coronavirus-binding antibodies using computational structural modelling
Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
Cryptic SARS-CoV2-spike-with-sugar interactions revealed by 'universal' saturation transfer analysis
The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
Dynamic Profiling of  Binding and Allosteric Propensities  of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies:  Mutational and Perturbation-Based Scanning Reveal Allosteric Duality of Functionally Adaptable Hotspots
An mRNA SARS-CoV-2 vaccine employing a novel delivery vehicle with a TLR-9 agonist induces neutralizing antibodies and T cell memory
A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
SARS-CoV-2 spike protein expressing epithelial cells promotes senescence associated secretory phenotype in endothelial cells and increased inflammatory response
Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variants
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein
Molecular relationships between SARS-CoV-2 Spike protein and LIFR, a pneumonia protective IL-6 family cytokine
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines
Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 isolates from Pennsylvania
Human Taste Cells Express ACE2: A Portal for SARS-CoV-2 Infection
Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 binding
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
Binding mechanism of neutralizing Nanobodies targeting SARS-CoV-2 Spike Glycoprotein
A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses
Production of a Highly Immunogenic Antigen from SARS-CoV-2 by Covalent Coupling of the Receptor Binding Domain of Spike Protein to a Multimeric Carrier
A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope
Insertions in SARS-CoV-2 genome caused by template switch and duplications give rise to new variants of potential concern
Relative Mutant N501Y SARS-CoV-2 Spike Protein RBD Inhibition of Anti-Spike Protein IgG and ACE-2 Binding to Spike Protein Species
Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity
Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variants
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose.
Possible link between higher transmissibility of B.1.617 and B.1.1.7 variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity
Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine
Allosteric Cross-Talk Among SARS-CoV-2 Spike's Receptor-Binding Domain Mutations Triggers an Effective Hijacking of Human Cell Receptor
LY-CoV1404 potently neutralizes SARS-CoV-2 variants
SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity
SARS -CoV-2 T-cell immunity to variants of concern following vaccination
Preliminary Immunogenicity of a Pan-COVID-19 T Cell Vaccine in HLA-A*02:01 Mice
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection
Immunolocalization studies of vimentin and ACE2 on the surface of cells exposed to SARS-CoV-2 Spike proteins
Durable antibody responses in staff at two long-term care facilities, during and post SARS-CoV-2 outbreaks
SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination
Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and QuadrivalentSeasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant
SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies
SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant
Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity
Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Rapid Electronic Diagnostics of Ebola Virus with Synthetic Nanobody-Conjugated Gold Nanoparticles
A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1
Receptor binding may directly activate the fusion machinery in coronavirus spike glycoproteins
Impacts on the structure-function relationship of SARS-CoV-2 spike by B.1.1.7 mutations
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
Energy Landscape of the SARS-CoV-2 Reveals Extensive Conformational Heterogeneity
in silico Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 variants
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate
In Silico Molecular-Based Rationale for SARS-CoV-2 Spike Circulating Mutations Able to Escape Bamlanivimab and Etesevimab Monoclonal Antibodies
Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice
Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity
Single-dose AAV-based vaccine induces a high level of neutralizing antibodies and provides long-term protection against SARS-CoV-2 in rhesus macaques
The Structure of ChAdOx1/AZD-1222 Reveals Interactions with CAR and PF4 with Implications for Vaccine-induced Immune Thrombotic Thrombocytopenia
Deamidation drives molecular aging of the SARS-CoV-2 spike receptor-binding motif
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant
Evidence for Deleterious Original Antigenic Sin in SARS-CoV-2 Immune Response
Reprogrammed tracrRNAs enable repurposing RNAs as crRNAs and detecting RNAs
Impact of Glycosylation on SARS-CoV-2 Infection and Broadly Protective Vaccine Design
Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima, Peru
Variable Induction of Pro-inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Combination of a Sindbis-SARS-CoV-2 spike vaccine and Î±OX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity
Mutational hotspot in the SARS-CoV-2 Spike protein N-terminal domain conferring immune escape potential
Decomposition of the SARS-CoV-2-ACE2 interface reveals a common trend among emerging viral variants
Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike protein
SARS-CoV-2-specific memory B cells can persist in the elderly despite loss of neutralising antibodies
Functional characterization of SARS-CoV-2 vaccine elicited antibodies in immunologically naive and pre-immune humans
Accelerated Antibody Discovery Targeting the SARS-CoV-2 Spike Protein for COVID-19 Therapeutic Potential
SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization
SARS-CoV-2 Spreads through Cell-to-Cell Transmission
Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking
Efficacy of ancestral receptor-binding domain, S1 and trimeric spike protein vaccines against SARS-CoV-2 variants B.1.1.7, B.1.351, and B.1.617.1
Visualization of SARS-CoV-2 infection dynamic
Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19
E156/G and Arg158, Phe-157/del mutation in NTD of spike protein in B.1.167.2 lineage of SARS-CoV-2 leads to immune evasion through antibody escape
Mapping Potential Antigenic Drift Sites (PADS) on SARS-CoV-2 Spike in Continuous Epitope-Paratope Space
Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies.
Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection
Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine
Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made in the absence of T follicular helper cells
B.1.1.7 and B.1.351 SARS-CoV-2 variants display enhanced Spike-mediated fusion
A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Proteinco-immunization in rhesus macaques
COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
Designing a Novel Multi-Epitope Vaccine against SARS-CoV-2; Implication for Viral Binds and Fusion Inhibition through Inducing Neutralizing Antibodies
A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants
Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2
Differences in IgG antibody responses following BNT162b2 and mRNA-1273 Vaccines
Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system
Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins
Escherichia coli recombinant expression of SARS-CoV-2 protein fragments.
E484K and N501Y SARS-CoV 2 Spike Mutants Increase ACE2 Recognition but Reduce Affinity for Neutralizing Antibody
Engineered chimeric T cell receptor fusion construct (TRuC)-expressing T cells prevent translational shutdown in SARS-CoV-2-infected cells
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2
A bifluorescent-based assay for the identification of neutralizing antibodies against SARS-CoV-2 variants of concern in vitro and in vivo
Rapid determination of the wide dynamic range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and naturally infected
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
Highly-Neutralizing COVID-19-Convalescent-Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
A cGAMP-containing hydrogel for prolonged SARS-CoV-2 RBD subunit vaccine exposure induces a broad and potent humoral response
A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening
Predicted Impact of the Viral Mutational Landscape on the Cytotoxic Response against SARS-CoV-2
Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
Receptor-binding domain recombinant protein RBD219-N1C1 on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD
Atomistic Simulations and Deep Mutational Scanning of Protein Stability and Binding Interactions in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms
Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccine
Therapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2
The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes
SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: a Computational Model of Epitope Loss in Variants of Concern
Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model
Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
Xeno-nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding
Visualizing Amino Acid Substitutions in a Physicochemical Vector Space
Molecular evolution and structural analyses of the spike glycoprotein from Brazilian SARS-CoV-2 genomes: the impact of the fixation of selected mutations
Mutation-induced Changes in the Receptor-binding Interface of the SARS-CoV-2 Delta Variant B.1.617.2 and Implications for Immune Evasion
SARS-CoV-2 Spike Pseudoviruses: A Useful tool to study virus entry and address emerging neutralization escape phenotypes
Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects
Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism
Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants
Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy
A single oral immunization with a replication-competent adenovirus-vectored vaccine protects mice from influenza respiratory infection
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies
Mutations in two SARS-CoV-2 variants of concern reflect two distinct strategies of antibody escape
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection
Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines
SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors
Spike protein multiorgan tropism suppressed by antibodies targeting SARS-CoV-2
Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants
MVsim: a toolset for quantifying and designing multivalent interactions
Regional Variant Analysis of Spike Glycoprotein Mutations of SARS-CoV-2 and Its Implications in COVID-19 Pandemic Control
Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit.
Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern
Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity
Llamanade: an open-source computational pipeline for robust nanobody humanization
Limited variation between SARS-CoV-2-infected individuals in domain specificity and relative potency of the antibody response against the spike glycoprotein
Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2
The Inherent Flexibility of Receptor Binding Domains in SARS-CoV-2 Spike Protein
High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies
Induction of cross-reactive antibody responses against the RBD domain of the spike protein of SARS-CoV-2 by commensal microbiota
Fully Human Antibody Immunoglobulin from Transchromosomic Bovines is Potent Against SARS-CoV-2 Variant Pseudoviruses
Broad neutralizing nanobody against SARS-CoV-2 engineered from pre-designed synthetic library
Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles
A broadly neutralizing biparatopic Nanobody protects mice from lethal challenge with SARS-CoV-2 variants of concern
Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies)
An ultrapotent neutralizing bispecific antibody with broad spectrum against SARS-CoV-2 variants
Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants
Molecular mimicry between Spike and human thrombopoietin may induce thrombocytopenia in COVID-19
Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and variants of concern
SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact
SARS-CoV-2 Neutralization in Commercial Lots of Plasma-derived Immunoglobulin
Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates
Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model
Peptide Scanning of SARS-CoV and SARS-CoV-2 Spike Protein Subunit 1 Reveals Potential Additional Receptor Binding Sites
Mutations in SARS-CoV-2 Variants Modulate the Microscopic Dynamics of Neutralizing Antibodies
Molecular basis of a dominant SARS-CoV-2 Spike-derived epitope presented by HLA-A*02:01 recognised by a public TCR
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant
Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected Patients
Protein-based RBD-C-tag COVID-19 Vaccination Candidate Elicits Protection Activity against SARS-COV-2 Variant Infection
Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
Directing an mRNA-LNP vaccine toward lymph nodes improves humoral and cellular immunity against SARS-CoV-2
Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine Candidate
Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization
Single-shot rAAV5-based Vaccine Provides Long-term Protective Immunity against SARS-CoV-2 and Its Variants
The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines
An Intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection
Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity
Epitopedia: identifying molecular mimicry of known immune epitopes
The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease
Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape
Altered interaction between RBD and ACE2 receptor contributes towards the increased transmissibility of SARS CoV-2 delta, kappa, beta, and gamma strains with RBD double mutations.
Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles
Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response.
Nanobody-Functionalized Cellulose for Capturing and Containing SARS-CoV-2
Structural and Biochemical Rationale for Enhanced Spike Protein Fitness in Delta and Kappa SARS-CoV-2 Variants
Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor
SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs
Network analysis outlines strengths and weaknesses of emerging SARS-CoV-2 Spike variants
ScanNet: An interpretable geometric deep learning model for structure-based protein binding site prediction
The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses
Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis
No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults
An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice
Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses
A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity
An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice
Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
Structure-activity relationships of B.1.617 and other SARS-CoV-2 spike variants
Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector
Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display
Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
Humoral immune responses against seasonal coronaviruses predict efficiency of SARS-CoV-2 spike targeting, FcÎ³R activation, and corresponding COVID-19 disease severity
Neutralizing antibody-independent immunity to SARS-CoV-2 in hamsters and hACE-2 transgenic mice immunized with a RBD/Nucleocapsid fusion protein
ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection
The nuts and bolts of SARS-CoV-2 Spike Receptor Binding Domain heterologous expression
SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
Identification of HLA-A*24:02-restricted CTL candidate epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2 and analysis of their conservation using the mutation database of SARS-CoV-2 variants
Personal care formulations demonstrate virucidal efficacy against multiple SARS-CoV-2 variants of concern: implications for hand hygiene
Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
Viral replication in human macrophages enhances an inflammatory cascade and interferon driven chronic COVID-19 in humanized mice.
ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Use of eVLP-based vaccine candidates to broaden immunity against SARS-CoV-2 variants
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques
Protection of Hamsters Challenged with SARS-CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Followed by a Single Dose of Beta Variant Version of MVC-COV1901
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
Ad26.COV2.S Prevents SARS-CoV-2 Induced Pathways of Inflammation and Thrombosis in Hamsters
Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
B.1.617.3 SARS CoV-2 spike E156G/Î”157-158 mutations contribute to reduced neutralization sensitivity and increased infectivity
Immunogenicity of trimetric spike protein associated to Poly(I:C) plus Alum
SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury
Immunodominant and neutralizing linear B cell epitopes spanning the spike and membrane proteins of Porcine Epidemic Diarrhea Virus
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination
Non-invasive Imaging of Sense of Smell by Tracking the Voltage-Gated Sodium Channel NaV1.7
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo
SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy
The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
A Rapid Bead-Based Assay For Screening Of SARS-CoV-2 Neutralising Antibodies
Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis
Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine
Plant-based production of SARS-CoV-2 antigens for use in a subunit vaccine
Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
Preparation of ingestible antibodies to neutralize the binding of SarsCoV2 RBD (receptor binding domain) to human ACE2 Receptor
Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection
An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant viral replication in rhesus macaques
Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination
The humanized nanobody RBD-1-2G tolerates the spike N501Y mutation to neutralize SARS-CoV-2
COVID 19 breakthrough infection risk: a simple physical model describing the dependence on antibody concentration
Nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants
